2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

Authors, Journal, Affiliations, Type, DOI

• Chairpersons: Katja Zeppenfeld (Leiden University Medical Centre) and Jacob Tfelt-Hansen (Copenhagen University Hospital, Rigshospitalet)
• Task Force: 25 members (23 expert physicians, 1 methodologist, 1 patient representative) representing all VA/SCD subspecialties
• Journal: European Heart Journal (2022), 43:3997–4126
• Affiliations: European Society of Cardiology (ESC); endorsed by AEPC
• Type: Clinical Practice Guideline (update of 2015 ESC VA/SCD Guidelines)
• DOI: https://doi.org/10.1093/eurheartj/ehac262

Overview

The 2022 ESC Guidelines on ventricular arrhythmias (VA) and sudden cardiac death (SCD) prevention is the most comprehensive CPG in this field, covering 50+ disease entities with 50 recommendation tables and 1,155 references (485 supporting recommendations). Key updates from 2015 include catheter ablation elevated to Class I for CAD patients with SMVT refractory to amiodarone, a multi-risk-factor ICD threshold for DCM/HNDCM (LVEF <50% + ≥2 risk factors), and SGLT2 inhibitors added as Class I heart failure medication. The guideline introduces five standardized diagnostic flowcharts for first-presentation VA scenarios, formalizes the HNDCM phenotype, and provides updated management algorithms for all primary electrical diseases and structural heart diseases associated with SCD.

Keywords

Guidelines · Anti-arrhythmic drugs · Cardiac magnetic resonance · Cardiomyopathies · Catheter ablation · Chronic coronary artery disease · Genetic testing · Implantable cardioverter defibrillator · Premature ventricular complex · Primary electrical disease · Recommendations · Risk calculator · Risk stratification · Sudden cardiac death · Sudden death · Ventricular arrhythmia · Ventricular fibrillation · Ventricular tachycardia

Key Takeaways

Definitions

• Ventricular tachycardia (VT): ≥3 consecutive beats, rate >100 bpm, originating from ventricles independent of AV conduction. NSVT = 3 beats to 30 s; sustained VT = ≥30 s or requiring termination.
• Electrical storm: ≥3 VA episodes within 24 h (each separated by ≥5 min), each requiring termination by intervention.
• SCD: Natural unexpected death presumed cardiac within 1 h of symptoms (witnessed) or within 24 h of last seen alive (unwitnessed).
• SADS (Sudden Arrhythmic Death Syndrome): Unexplained sudden death >1 year old with negative pathological and toxicological assessment; synonymous with autopsy-negative sudden unexplained death.

Epidemiology of SCD

• SCD accounts for ~50% of all cardiovascular deaths; up to 50% are the first manifestation of cardiac disease.
• Incidence: ~1/100,000 person-years in children; ~50/100,000 in middle-aged individuals; ≥200/100,000 in the 8th decade.
• Males have higher SCD rates at any age, even after adjustment for CAD risk factors.
• 10–20% of all European deaths are SCD; ~300,000 OHCA treated by EMS annually in Europe.
• CAD is responsible for 75–80% of SCD; in individuals <50 years, inherited electrical diseases and structural non-ischaemic diseases account for >50% of SCD.
• SCD incidence is declining, but the proportion of SCD among total cardiovascular deaths may be increasing.

Diagnostic Tools

• Genetic testing (Class I): Recommended in DCM/HNDCM with AV conduction delay <50 years or family history; in ARVC (suspected or definite); in HCM; in all channelopathies. Panel must include LMNA, PLN, RBM20, FLNC for DCM/HNDCM.
• CMR (Class I): Recommended in suspected ARVC, HCM diagnostic work-up; Class IIa in DCM/HNDCM for aetiology and risk assessment.
• Five diagnostic scenarios for first-presentation VA without known cardiac disease: (1) Incidental NSVT, (2) first sustained SMVT, (3) SCA survivor, (4) sudden death victim, (5) relatives of SADS decedents.
• Provocative diagnostic tests: IV ajmaline/flecainide for BrS unmasking; IV epinephrine for LQTS/CPVT; IV adenosine for idiopathic VT; IV isoproterenol for IVF/BrS.

Acute Management of VA

• DC cardioversion (Class I): First-line for tolerated SMVT when anaesthetic/sedation risk is low (NEW 2022 Class I).
• Procainamide IV (Class IIa): For haemodynamically tolerated SMVT with known/suspected structural heart disease.
• Amiodarone IV (Class IIb): For haemodynamically tolerated SMVT without established diagnosis.
• Electrical storm management: Deep sedation, IV beta-blockers (Class I), IV amiodarone (Class I), consider emergency catheter ablation. Isoproterenol IV for CPVT/IVF-driven storm.
• Reversible causes (Class I): Correct electrolyte disturbances, ischaemia, drug toxicity before any device implantation.

Long-term Pharmacotherapy

• HF medication (Class I, Level A): ACE-I/ARB/ARNI + MRA + beta-blockers + SGLT2 inhibitors in all HFrEF patients (SGLT2i is NEW in 2022).
• Beta-blockers: First-line AAD for all structural heart disease; non-selective agents (nadolol, propranolol) preferred in LQTS and CPVT.
• Amiodarone: Effective for VA suppression across most SHD; NOT first-line in idiopathic PVC/VT (Class III).
• Mexiletine (Class I): Indicated in LQT3 patients with prolonged QT interval (NEW 2022 Class I).
• Quinidine: For chronic therapy in IVF/BrS/ERS (Class IIa); first pharmacotherapy option in SQTS.
• Flecainide: First add-on therapy in CPVT; first-line for idiopathic RVOT VT/PVC (Class I); NOT recommended in SHD.

ICD — General Principles

• ICD only if expected good-quality survival >1 year (Class I): New 2022 explicit threshold.
• Secondary prevention (Class I): ICD in documented VF or haemodynamically not-tolerated VT without reversible causes.
• ICD programming optimization (Class I, Level A): Prolonged detection (≥6–12 s / 30 intervals); slowest therapy zone ≥188 bpm in primary prevention; ATP in all tachycardia zones in SHD; SVT discrimination algorithms up to 230 bpm; remote monitoring.
• S-ICD: Dual zone configuration with discrimination in lower zone (Class I). Preferred over transvenous ICD when no pacing/ATP indication.
• WCD (Class IIb): May be considered in early phase post-MI in selected patients (NEW 2022 Class IIb).

Catheter Ablation

• Class I — CAD + recurrent SMVT refractory to amiodarone: Catheter ablation preferred over escalating AAD (NEW 2022 Class I upgrade from IIa).
• Class I — PVC-induced cardiomyopathy: Catheter ablation when cardiomyopathy suspected due to frequent monomorphic PVCs (upgraded from IIa).
• Class I — idiopathic RVOT/left fascicular VT/PVCs: Catheter ablation as first-line treatment (NEW 2022 Class I).
• Class I — incessant VT/electrical storm refractory to AADs: Catheter ablation recommended.
• Specialized centre required for structural heart disease: at least one operator with percutaneous epicardial access experience; interventional cardiology and cardiothoracic surgical back-up.

Coronary Artery Disease

• Primary prevention ICD: Class I for CAD + NYHA II–III + LVEF ≤35% after ≥3 months OMT; Class IIa for NYHA I + LVEF ≤30%.
• NEW 2022 Class IIa: ICD for CAD + LVEF ≤40% + OMT + NSVT if inducible SMVT at PES.
• Post-MI LVEF assessment: Class I before discharge; if LVEF ≤40%, reassess at 6–12 weeks.
• Catheter ablation as alternative to ICD for hemodynamically well-tolerated SMVT + LVEF ≥40%: Class IIa.

DCM / Hypokinetic Non-dilated Cardiomyopathy (HNDCM)

• HNDCM is a new phenotype formalized in this guideline: wall motion abnormalities without LV dilatation meeting DCM criteria.
• Genetic testing (Class I): LMNA, PLN, RBM20, FLNC in DCM/HNDCM with AV conduction delay <50 years or family history of SCD <50 years.
• Multi-risk-factor ICD threshold (Class IIa): ICD in DCM/HNDCM with LVEF <50% AND ≥2 risk factors: syncope, LGE on CMR, inducible SMVT at PES, pathogenic mutations in LMNA, PLN, FLNC, or RBM20.
• LMNA-specific (Class III): Competitive sports and high-intensity exercise NOT recommended for LMNA mutation carriers.
• Standard ICD threshold (Class IIa in 2022, downgraded from Class I 2015): DCM/HNDCM + NYHA II–III + LVEF ≤35% after ≥3 months OMT.

ARVC

• Exercise restriction (Class I, Level B): High-intensity exercise must be avoided in definite ARVC. (Avoidance of high-intensity exercise in phenotype-negative mutation carriers: Class IIb.)
• CMR (Class I): Recommended in all suspected ARVC.
• Genetic testing (Class I): In suspected or definite ARVC.
• Beta-blockers (Class I): In ARVC with NSVT or sustained VA.
• ICD (Class I): For haemodynamically not-tolerated VT or VF; Class IIa for symptomatic patients with moderate RV/LV dysfunction + NSVT or inducible SMVT.
• ATP programming (Class IIa): ICD with ATP capability for SMVT up to high rates recommended.

HCM

• HCM Risk-SCD (Class I): Assess 5-year risk at first evaluation and every 1–3 years.
• ICD indications:
  • Haemodynamically not-tolerated VT/VF: Class I.
  • 5-year risk ≥6% (adults ≥16 yr): Class I.
  • 5-year risk ≥4–6% + significant LGE (≥15% LV mass), or LVEF <50%, or abnormal BP response to exercise, or LV apical aneurysm, or sarcomeric pathogenic mutation: Class IIa.
  • Children <16 yr: HCM Risk-Kids score ≥6% → Class IIa.
  • Haemodynamically tolerated SMVT: Class IIa.
• LGE (Class I): CMR with LGE recommended in diagnostic work-up.
• Genetic testing (Class I): Recommended in all HCM patients and first-degree relatives.

Primary Electrical Diseases — ESC 2022 Key Recommendations

LQTS:

• Diagnosed with QTc ≥480 ms on repeated 12-lead ECG, OR Schwartz diagnostic score ≥3, OR pathogenic mutation (irrespective of QT duration): all Class I.
• Non-selective beta-blockers (nadolol or propranolol): Class I.
• Mexiletine in LQT3 with prolonged QT: Class I (NEW).
• ICD + beta-blockers after cardiac arrest: Class I. ICD if symptomatic on beta-blockers + genotype-specific therapies: Class I.
• LCSD (Class I): When ICD contraindicated/declined OR patient on therapy with ICD experiencing multiple shocks/syncope.
• Arrhythmic risk calculator (1-2-3 LQTS Risk): Class IIa before therapy.
• Epinephrine challenge NOT recommended: Class III. EPS NOT recommended: Class III.

Brugada Syndrome:

• Diagnosis: spontaneous type 1 BrS ECG without structural disease: Class I; fever-induced type 1 after SCA: Class I; SCN5A genetic testing: Class I for probands.
• Avoid BrS-aggravating drugs (brugadadrugs.org), fever, cocaine, cannabis, excess alcohol: Class I.
• ICD for SCA survivors or documented sustained VT: Class I.
• ILR for unexplained syncope in BrS: Class IIa.
• BrS diagnosis may be considered with induced type 1 alone (no other criteria): Class IIb.
• Sodium channel blocker test NOT recommended if prior type 1 pattern: Class III.
• Catheter ablation in asymptomatic BrS: NOT recommended (Class III).

Andersen-Tawil Syndrome (LQT7):

• Genetic testing (KCNJ2): Class I.
• ICD after aborted CA or not-tolerated sustained VT: Class I.
• Consider diagnosis with ≥2 of: prominent U waves, bidirectional/polymorphic PVCs, dysmorphic features, periodic paralysis, KCNJ2 pathogenic mutation: Class IIa.
• Beta-blockers ± flecainide ± acetazolamide: Class IIa.

ERS:

• ERP defined as J-point elevation ≥1 mm in ≥2 adjacent inferior/lateral leads: Class I.
• ERS diagnosed in resuscitated VF/PVT + ERP: Class I.
• ICD after SCA: Class I.
• No routine clinical evaluation for asymptomatic ERP: Class III.
• ICD NOT recommended in asymptomatic isolated ERP: Class III.
• Isoproterenol for ERS electrical storm: Class IIa.
• Quinidine + ICD for recurrent VF: Class IIa.

CPVT:

• Non-selective beta-blockers (nadolol or propranolol): Class I.
• Avoid competitive sports, strenuous exercise, stressful environments: Class I.
• ICD + beta-blockers + flecainide after aborted CA: Class I (NEW 2022 upgrade).
• LCSD when flecainide + beta-blockers are ineffective/not tolerated: Class IIa.
• ICD when arrhythmic syncope or bidirectional/PVT despite max beta-blocker + flecainide: Class IIa.
• PES NOT recommended: Class III.

SQTS:

• Diagnosis: QTc ≤360 ms + ≥1 of: pathogenic mutation, family history SQTS, VT/VF without structural disease: Class I. (Previous: QTc <340 ms alone.)
• Genetic testing: Class I.
• ICD for SCA survivors or documented sustained VT: Class I.
• QTc ≤320 ms alone: consider SQTS (Class IIa).
• Quinidine: Class IIb alternative if ICD contraindicated or refused.

Idiopathic VF:

• Diagnose IVF after exclusion of structural, channelopathic, metabolic, and toxicological aetiologies: Class I.
• ICD: Class I.
• Isoproterenol/verapamil/quinidine for acute electrical storm or recurrent ICD discharges: Class IIa.
• Quinidine for chronic therapy: Class IIa.

Inflammatory and Other Structural Diseases

• Cardiac sarcoidosis: ICD if LVEF ≤35% (Class I); ICD if documented sustained VT or aborted CA (Class I); ICD if LVEF >35% + significant LGE after resolution of inflammation (Class IIa); PES for risk stratification if LVEF 35–50% + minor LGE (Class IIa).
• Myocarditis (chronic phase): ICD for haemodynamically not-tolerated SMVT: Class I. Catheter ablation in specialised centres for recurrent SMVT: Class IIa.
• Chagas cardiomyopathy: Amiodarone for symptomatic PVCs/VT: Class IIa. Catheter ablation for recurrent SMVT refractory to AADs: Class IIa.
• Congenital heart disease (CHD): ICD for biventricular CHD + LVEF ≤35% + NYHA II/III: Class I. Catheter ablation for repaired TOF with SMVT in specialized centres: Class I.

Special Populations

• Athletes: Cardiovascular evaluation before competition: Class IIa. Athletes diagnosed with SCD-associated CVD managed per guidelines: Class I.
• Pregnancy: DC cardioversion for sustained VT: Class I. Continue beta-blockers in LQTS/CPVT through pregnancy/postpartum: Class I. If ICD indicated, implant with optimal radiation protection: Class I.
• Elderly: Omission of primary prevention ICD in patients where ICD benefit unlikely due to age/comorbidities: Class IIb.
• Neuromuscular diseases: Annual 12-lead ECG in muscular dystrophies: Class I. EPS in myotonic dystrophy with palpitations/syncope: Class I. ICD in myotonic dystrophy + SMVT or aborted CA (non-BBR-VT): Class I.

Limitations of the Document

• Majority of recommendations are Level B or C — limited randomized trial data in this field; most evidence from registries and retrospective cohorts.
• SCD risk calculators have inherent limitations: historic samples not representative of contemporary cohorts, missing values, variable calibration, limited external validation.
• Competing risks (non-SCD deaths from comorbidities) complicate ICD benefit estimation, particularly in the elderly.
• Risk calculators use different cut-offs (5-year SCD vs. 5-year VA) — not directly comparable across diseases.
• DCM/HNDCM multi-risk-factor ICD threshold (LVEF <50%) represents expert consensus with limited prospective validation.
• Gene-specific risk thresholds (LMNA, PLN, FLNC, RBM20) are based on small single-centre cohorts.
• HCM Risk-SCD should NOT be applied in athletes or metabolic/infiltrative cardiomyopathies.

Key Concepts Mentioned

• concepts/Electrical-Storm — new dedicated management section in this guideline
• concepts/Sudden-Cardiac-Death — comprehensive epidemiology update
• concepts/Left-Cardiac-Sympathetic-Denervation — Class I indication formalized for LQTS
• concepts/HCM-Risk-SCD — ICD thresholds refined
• concepts/Late-Gadolinium-Enhancement — central risk stratification tool across diseases
• concepts/ARVC-Task-Force-Criteria — referenced for ARVC diagnosis
• concepts/Cascade-Family-Screening — systematic evaluation framework
• concepts/LVOTO — management referenced for HCM

Key Entities Mentioned

• entities/Long-QT-Syndrome — mexiletine Class I in LQT3; 1-2-3 LQTS calculator Class IIa
• entities/Brugada-Syndrome — SCN5A testing Class I; ablation not for asymptomatic (Class III)
• entities/CPVT — ICD+flecainide+beta-blocker after CA now Class I
• entities/Short-QT-Syndrome — revised diagnosis criteria (QTc ≤360 ms + criteria)
• entities/Early-Repolarization-Syndrome — ICD after SCA Class I; no therapy for asymptomatic
• entities/Idiopathic-Ventricular-Fibrillation — systematic exclusion criteria; ICD Class I
• entities/Andersen-Tawil-Syndrome — dedicated section; KCNJ2 testing Class I
• entities/ARVC — exercise avoidance now Class I; ATP-capable ICD Class IIa
• entities/HCM — ICD at 5-year risk ≥6% Class I; risk assessment annually Class I
• entities/DCM — multi-risk-factor ICD threshold formalized (LVEF <50% + ≥2 factors)
• entities/LMNA — competitive sports contraindicated (Class III) with LMNA mutation
• entities/SCN5A — BrS genetic testing Class I
• entities/KCNQ1, entities/KCNH2 — LQTS management
• entities/RYR2 — CPVT management

Wiki Pages Updated

• wiki/sources/VA-SCD-ESC-2022.md (created)
• wiki/concepts/Electrical-Storm.md (created)
• wiki/entities/Andersen-Tawil-Syndrome.md (created)
• wiki/entities/Long-QT-Syndrome.md (updated)
• wiki/entities/Brugada-Syndrome.md (updated)
• wiki/entities/CPVT.md (updated)
• wiki/entities/Short-QT-Syndrome.md (updated)
• wiki/entities/Early-Repolarization-Syndrome.md (updated)
• wiki/entities/Idiopathic-Ventricular-Fibrillation.md (updated)
• wiki/entities/ARVC.md (updated)
• wiki/entities/HCM.md (updated)
• wiki/entities/DCM.md (updated)
• wiki/entities/LMNA.md (updated)
• wiki/concepts/Sudden-Cardiac-Death.md (updated)
• wiki/concepts/Left-Cardiac-Sympathetic-Denervation.md (updated)
• wiki/index.md (updated)
• wiki/log.md (updated)